ZBIO
Zenas BioPharma, Inc.
Price Chart
Latest Quote
$18.15
Current Price| Previous Close | $18.37 |
| Open | $18.33 |
| Day High | $18.71 |
| Day Low | $17.60 |
| Volume | 844,708 |
Stock Information
| Shares Outstanding | 53.68M |
| Total Debt | $798K |
| Cash Equivalents | $290.88M |
| Revenue | $15.00M |
| Net Income | $-189.90M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $974.28M |
| P/E Ratio | 1.34 |
| EPS (TTM) | $13.51 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 17/42| Debt to Equity | 0.00 |
| Debt to Earnings | -0.01 |
| Current Ratio | 6.21 |
| Quick Ratio | 6.12 |
| Profit Margin | -3139.76% |
| Return on Equity | -50.24% |
| Avg FCF Growth | 25.52% |
| FCF Yield | -12.30% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $18.15 | 852,777 |
| 2026-01-30 | $18.37 | 483,100 |
| 2026-01-29 | $20.88 | 480,800 |
| 2026-01-28 | $21.47 | 470,500 |
| 2026-01-27 | $20.07 | 388,600 |
| 2026-01-26 | $19.32 | 433,100 |
| 2026-01-23 | $20.09 | 453,800 |
| 2026-01-22 | $20.40 | 900,600 |
| 2026-01-21 | $19.59 | 831,500 |
| 2026-01-20 | $20.88 | 723,700 |
| 2026-01-16 | $20.16 | 699,500 |
| 2026-01-15 | $19.93 | 1,573,300 |
| 2026-01-14 | $22.56 | 774,300 |
| 2026-01-13 | $21.57 | 1,414,600 |
| 2026-01-12 | $19.78 | 1,919,800 |
| 2026-01-09 | $16.08 | 532,900 |
| 2026-01-08 | $16.41 | 813,500 |
| 2026-01-07 | $16.51 | 2,041,100 |
| 2026-01-06 | $15.20 | 3,137,800 |
| 2026-01-05 | $16.61 | 8,145,100 |
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
📰 Latest News
Assessing Zenas BioPharma (ZBIO) Valuation After Positive INDIGO Phase 3 Trial News
Simply Wall St. • 2026-01-13T06:09:08Z
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes
Benzinga • 2026-01-07T11:46:11Z
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
Zacks • 2026-01-06T16:18:00Z
Wall Street Consolidates, Driving Muted Premarket Action for US Equity Futures
MT Newswires • 2026-01-06T14:16:32ZZenas’ stock drops 51% despite lead asset’s Phase III rare disease win
Clinical Trials Arena • 2026-01-06T11:25:27Z
How Much Could Obexelimab’s Phase 3 Win Reshape Zenas BioPharma’s (ZBIO) Autoimmune Franchise Ambitions?
Simply Wall St. • 2026-01-06T08:06:04Z
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.
Investor's Business Daily • 2026-01-05T21:20:14Z
Top Midday Decliners
MT Newswires • 2026-01-05T19:00:27ZUS Equity Futures Mixed Pre-Bell Monday Despite Oil Sector Surge
MT Newswires • 2026-01-05T13:51:33ZZenas shares crash after top drug misses expectations in immune disease study
BioPharma Dive • 2026-01-05T11:26:00Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | $5,000,000 | $50,000,000 | $0 |
| Operating Revenue | $5,000,000 | $50,000,000 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Expenses | $168,888,000 | $77,147,000 | $75,199,000 |
| Other Income Expense | $7,329,000 | $-9,676,000 | $-44,083,000 |
| Other Non Operating Income Expenses | $8,175,000 | $624,000 | $61,000 |
| Operating Expense | $168,888,000 | $77,147,000 | $75,199,000 |
| General And Administrative Expense | $29,749,000 | $17,114,000 | $13,510,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Normalized Income | $-156,319,660 | $-28,987,000 | $-75,138,000 |
| Net Income From Continuing And Discontinued Operation | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Total Operating Income As Reported | $-163,888,000 | $-37,147,000 | $-76,199,000 |
| Net Income Common Stockholders | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Net Income | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Net Income Including Noncontrolling Interests | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Net Income Continuous Operations | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Pretax Income | $-156,559,000 | $-36,823,000 | $-119,282,000 |
| Special Income Charges | $0 | $-10,000,000 | $-1,000,000 |
| Operating Income | $-163,888,000 | $-27,147,000 | $-75,199,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Diluted EPS | $-11.89 | $-2.13 | $-9.26 |
| Basic EPS | $-11.89 | $-2.13 | $-9.26 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Tax Effect Of Unusual Items | $-177,660 | $-2,163,000 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-162,905,000 | $-16,734,000 | $-30,977,000 |
| Total Unusual Items | $-846,000 | $-10,300,000 | $-44,144,000 |
| Total Unusual Items Excluding Goodwill | $-846,000 | $-10,300,000 | $-44,144,000 |
| Reconciled Depreciation | $137,000 | $113,000 | $78,000 |
| EBITDA (Bullshit earnings) | $-163,751,000 | $-27,034,000 | $-75,121,000 |
| EBIT | $-163,888,000 | $-27,147,000 | $-75,199,000 |
| Diluted Average Shares | $13,198,960 | $17,415,875 | $12,879,648 |
| Basic Average Shares | $13,198,960 | $17,415,875 | $12,879,648 |
| Diluted NI Availto Com Stockholders | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Tax Provision | $429,000 | $301,000 | $0 |
| Restructuring And Mergern Acquisition | $0 | $10,000,000 | $1,000,000 |
| Gain On Sale Of Security | $-846,000 | $-300,000 | $-43,144,000 |
| Research And Development | $139,139,000 | $60,033,000 | $61,689,000 |
| Selling General And Administration | $29,749,000 | $17,114,000 | $13,510,000 |
| Other Gand A | $11,136,000 | $7,255,000 | $6,021,000 |
| Salaries And Wages | $18,613,000 | $9,859,000 | $7,489,000 |
| Other Special Charges | - | $10,000,000 | $1,000,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Tangible Assets | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Total Assets | $369,968,000 | $68,180,000 | $74,579,000 |
| Total Non Current Assets | $14,045,000 | $8,376,000 | $6,135,000 |
| Other Non Current Assets | $217,000 | $186,000 | $212,000 |
| Non Current Prepaid Assets | $12,639,000 | $5,788,000 | $4,122,000 |
| Non Current Deferred Assets | $0 | $1,388,000 | $0 |
| Current Assets | $355,923,000 | $59,804,000 | $68,444,000 |
| Other Current Assets | $5,067,000 | $2,947,000 | $1,235,000 |
| Restricted Cash | $90,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $350,766,000 | $56,857,000 | $67,209,000 |
| Cash And Cash Equivalents | $319,742,000 | $56,857,000 | $67,209,000 |
| Cash Financial | - | $56,857,000 | $67,209,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Debt | $1,003,000 | $21,113,000 | $1,527,000 |
| Long Term Debt And Capital Lease Obligation | $218,000 | $20,557,000 | $812,000 |
| Current Debt And Capital Lease Obligation | $785,000 | $556,000 | $715,000 |
| Long Term Debt | - | $20,300,000 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Liabilities Net Minority Interest | $57,510,000 | $293,901,000 | $266,865,000 |
| Total Non Current Liabilities Net Minority Interest | $218,000 | $270,643,000 | $240,898,000 |
| Current Liabilities | $57,292,000 | $23,258,000 | $25,967,000 |
| Payables And Accrued Expenses | $48,199,000 | $17,580,000 | $20,921,000 |
| Payables | $17,347,000 | $5,697,000 | $5,815,000 |
| Total Tax Payable | $211,000 | $301,000 | $0 |
| Income Tax Payable | $211,000 | $301,000 | $0 |
| Accounts Payable | $17,136,000 | $5,396,000 | $5,815,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Common Stock Equity | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Total Equity Gross Minority Interest | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Stockholders Equity | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Gains Losses Not Affecting Retained Earnings | $194,000 | $37,000 | $-41,000 |
| Other Equity Adjustments | $194,000 | $37,000 | $-41,000 |
| Retained Earnings | $-387,391,000 | $-230,403,000 | $-193,279,000 |
| Preferred Securities Outside Stock Equity | $0 | $250,086,000 | $240,086,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Ordinary Shares Number | $41,793,412 | $39,792,381 | $39,792,381 |
| Share Issued | $41,793,412 | $39,792,381 | $39,792,381 |
| Tangible Book Value | $312,458,000 | $-225,721,000 | $-192,286,000 |
| Invested Capital | $312,458,000 | $-205,421,000 | $-192,286,000 |
| Working Capital | $298,631,000 | $36,546,000 | $42,477,000 |
| Capital Lease Obligations | $1,003,000 | $813,000 | $1,527,000 |
| Total Capitalization | $312,458,000 | $-205,421,000 | $-192,286,000 |
| Additional Paid In Capital | $699,651,000 | $4,645,000 | $1,034,000 |
| Capital Stock | $4,000 | $0 | $0 |
| Common Stock | $4,000 | $0 | $0 |
| Preferred Stock | $0 | $0 | - |
| Long Term Capital Lease Obligation | $218,000 | $257,000 | $812,000 |
| Current Capital Lease Obligation | $785,000 | $556,000 | $715,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $8,308,000 | $5,122,000 | $4,331,000 |
| Current Accrued Expenses | $30,852,000 | $11,883,000 | $15,106,000 |
| Net PPE | $1,189,000 | $1,014,000 | $1,801,000 |
| Gross PPE | $1,189,000 | $1,014,000 | $1,801,000 |
| Other Properties | $1,189,000 | $1,014,000 | $1,801,000 |
| Other Short Term Investments | $31,024,000 | $0 | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | $-119,805,000 | $-30,546,000 | $-67,850,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Cash Flow | $-119,674,000 | $-30,529,000 | $-65,652,000 |
| Cash Flow From Continuing Operating Activities | $-119,674,000 | $-30,529,000 | $-65,652,000 |
| Operating Gains Losses | - | - | $13,268,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Capital Expenditure | $-131,000 | $-17,000 | $-2,198,000 |
| Investing Cash Flow | $-30,552,000 | $-17,000 | $-2,198,000 |
| Cash Flow From Continuing Investing Activities | $-30,552,000 | $-17,000 | $-2,198,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $419,017,000 | $0 | $59,391,000 |
| Financing Cash Flow | $412,958,000 | $20,116,000 | $59,391,000 |
| Cash Flow From Continuing Financing Activities | $412,958,000 | $20,116,000 | $59,391,000 |
| Net Other Financing Charges | $-6,334,000 | - | - |
| Net Preferred Stock Issuance | $178,381,000 | $0 | $59,391,000 |
| Preferred Stock Issuance | $178,381,000 | $0 | $59,391,000 |
| Net Common Stock Issuance | $240,636,000 | $0 | - |
| Common Stock Issuance | $240,636,000 | $0 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Issuance Of Debt | $0 | $20,000,000 | $0 |
| End Cash Position | $319,832,000 | $56,943,000 | $67,295,000 |
| Beginning Cash Position | $56,943,000 | $67,295,000 | $75,795,000 |
| Effect Of Exchange Rate Changes | $157,000 | $78,000 | $-41,000 |
| Changes In Cash | $262,732,000 | $-10,430,000 | $-8,459,000 |
| Proceeds From Stock Option Exercised | $275,000 | $116,000 | $0 |
| Net Issuance Payments Of Debt | $0 | $20,000,000 | $0 |
| Net Long Term Debt Issuance | $0 | $20,000,000 | $0 |
| Long Term Debt Issuance | $0 | $20,000,000 | $0 |
| Net Investment Purchase And Sale | $-30,421,000 | $0 | - |
| Sale Of Investment | $6,000,000 | $0 | - |
| Purchase Of Investment | $-36,421,000 | $0 | - |
| Net PPE Purchase And Sale | $-131,000 | $-17,000 | $-198,000 |
| Purchase Of PPE | $-131,000 | $-17,000 | $-198,000 |
| Change In Working Capital | $25,431,000 | $-8,039,000 | $7,967,000 |
| Change In Other Current Liabilities | $-673,000 | $-714,000 | $-717,000 |
| Change In Payables And Accrued Expense | $33,805,000 | $-3,976,000 | $13,145,000 |
| Change In Accrued Expense | $22,065,000 | $-3,558,000 | $12,055,000 |
| Change In Payable | $11,740,000 | $-418,000 | $1,090,000 |
| Change In Account Payable | $11,740,000 | $-418,000 | $1,090,000 |
| Change In Prepaid Assets | $-7,701,000 | $-3,349,000 | $-4,461,000 |
| Other Non Cash Items | $1,527,000 | $11,026,000 | $31,580,000 |
| Stock Based Compensation | $10,821,000 | $3,495,000 | $737,000 |
| Amortization Of Securities | $-602,000 | $0 | - |
| Depreciation Amortization Depletion | $137,000 | $113,000 | $78,000 |
| Depreciation And Amortization | $137,000 | $113,000 | $78,000 |
| Depreciation | $137,000 | $113,000 | $78,000 |
| Net Income From Continuing Operations | $-156,988,000 | $-37,124,000 | $-119,282,000 |
| Net Intangibles Purchase And Sale | - | $0 | $-2,000,000 |
| Purchase Of Intangibles | - | $0 | $-2,000,000 |
| Gain Loss On Investment Securities | - | - | $13,268,000 |